Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Abstract

Patients with mantle cell lymphoma (MCL) usually respond to initial combination chemotherapy, but the disease inevitably relapses and often follows an aggressive course. Here, clinical study results published since 2008 for patients with relapsed/refractory MCL were reviewed to compare available evidence for treatment guidance. Most trials identified were non-randomized, phase II studies performed at a limited number of sites, and many evaluated MCL as one of multiple non-Hodgkin lymphoma subtypes. Additional randomized, comparative trials are needed. Treatment selection generally depends on patient need, age and fitness, time of relapse, and line of therapy. Combination regimens typically produce higher response rates than single agents, and adding rituximab generally improves outcomes. The inclusion of ibrutinib, lenalidomide, temsirolimus, and bortezomib, represents an important advance for patients ineligible for, unable to tolerate, or failing high-intensity combination chemotherapy. A high need for effective treatments in relapsed/refractory MCL remains, particularly for elderly and frail patients.

Detaljer

Författare
  • Martin Dreyling
  • Igor Aurer
  • Sergio Cortelazzo
  • Olivier Hermine
  • Georg Hess
  • Mats Jerkeman
  • Steven Le Gouill
  • Vincent Ribrag
  • Marek Trněný
  • Carlo Visco
  • Jan Walewski
  • Francesco Zaja
  • Pier Luigi Zinzani
Enheter & grupper
Externa organisationer
  • Paris Descartes University
  • University of Mainz
  • Nantes University Hospital
  • Institut Gustave Roussy
  • Charles University in Prague
  • Ospedale San Bortolo
  • The Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology
  • Ludwig-Maximilian University of Munich
  • University Hospital Centre Zagreb
  • Humanitas Gavazzeni - Ospedale a Bergamo
  • University of Udine
  • University of Bologna
Forskningsområden

Ämnesklassifikation (UKÄ) – OBLIGATORISK

  • Cancer och onkologi

Nyckelord

Originalspråkengelska
Sidor (från-till)1814-1828
TidskriftLeukemia and Lymphoma
Volym59
Utgivningsnummer8
Tidigt onlinedatum2017 nov 27
StatusPublished - 2018
PublikationskategoriForskning
Peer review utfördJa